Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | Director | December 07, 2012 | December 07, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date December 07, 2012 · Filed December 07, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2012-12-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date February 28, 2013 · Filed March 02, 2013
Section 16 reporting ended · disclosed 2013-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 137,475 |
Reported balance
After 2013-02-28 transaction · row 1
1 source rowRow 1 · 2013-02-28 · Tax withholding · Disposed 9,188 · Balance 137,475 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 4,134 |
Reported balance
Holding disclosure · report date 2013-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,134 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2013.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2009 Filed Mar 3, 2009 16:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,719 | $50.58 | $137,527.02 |
DisclosureSEC source: 0001104659-09-013726 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,838 Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,839 | $0.00 Strike: $54.74 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 8 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,839 Underlying: Common Shares · 1,839 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,851 | $0.00 Strike: $54.74 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,851 Underlying: Common Shares · 1,851 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,454 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,454 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,050 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,050 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,690 | $54.74 | $201,990.60 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,557 Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,454 | $41.03 | $100,691.79 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2009 Filed Feb 28, 2009 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,050 | $33.23 | $101,355.77 |
DisclosureSEC source: 0001104659-09-013204 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 27,000 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011814 · a4.xml · derivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common shares · 27,000 shares Expires 2019-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,000 on 02/20/2010, 9,000 on 02/20/2011, and 9,000 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011814 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,743 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.45 | $5,445.45 |
DisclosureSEC source: 0001104659-09-010774 · a4.xml · nonDerivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,743 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.45 | $5,445.38 |
DisclosureSEC source: 0001104659-09-010774 · a4.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,843 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.46 | $10,891.00 |
DisclosureSEC source: 0001104659-09-010774 · a4.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,943 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 17 | $54.45 | $925.71 |
DisclosureSEC source: 0001104659-09-010774 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,143 Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,277 | $54.94 | $70,158.38 |
DisclosureSEC source: 0001104659-09-010774 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,160 Read SEC document |
| February 09, 2009 Filed Feb 12, 2009 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,758 | $0.00 Strike: $56.85 | $0.00 |
DisclosureSEC source: 0001104659-09-008434 · a4.xml · derivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,758 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 09, 2009 Filed Feb 12, 2009 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 8,143 | $0.00 Strike: $56.30 | $0.00 |
DisclosureSEC source: 0001104659-09-008434 · a4.xml · derivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,143 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 09, 2009 Filed Feb 12, 2009 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,758 | $57.00 | $100,206.00 |
DisclosureSEC source: 0001104659-09-008434 · a4.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,437 Read SEC document |
| February 09, 2009 Filed Feb 12, 2009 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,143 | $56.99 | $464,069.57 |
DisclosureSEC source: 0001104659-09-008434 · a4.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,195 Read SEC document |
| February 09, 2009 Filed Feb 12, 2009 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,758 | $56.85 | $99,942.30 |
DisclosureSEC source: 0001104659-09-008434 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2009 Filed Feb 12, 2009 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 8,143 | $56.30 | $458,450.90 |
DisclosureSEC source: 0001104659-09-008434 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 13,548 | $0.00 Strike: $58.71 | $0.00 |
DisclosureSEC source: 0001104659-08-051464 · a4.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,548 Underlying: Common Shares · 13,548 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 15,473 | $0.00 Strike: $46.65 | $0.00 |
DisclosureSEC source: 0001104659-08-051464 · a4.xml · derivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,473 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 13,548 | $58.71 | $795,403.08 |
DisclosureSEC source: 0001104659-08-051464 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,437 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 15,473 | $46.65 | $721,815.45 |
DisclosureSEC source: 0001104659-08-051464 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2008 Filed Aug 4, 2008 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,758 | $0.00 Strike: $56.85 | $0.00 |
DisclosureSEC source: 0001104659-08-049636 · a4.xml · derivative · entry 8 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,758 Underlying: Common Shares · 1,758 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 31, 2008 Filed Aug 4, 2008 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,758 | $0.00 Strike: $56.85 | $0.00 |
DisclosureSEC source: 0001104659-08-049636 · a4.xml · derivative · entry 7 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,758 Underlying: Common Shares · 1,758 shares Expires 2009-02-11 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 31, 2008 Filed Aug 4, 2008 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,065 | $0.00 Strike: $32.61 | $0.00 |
DisclosureSEC source: 0001104659-08-049636 · a4.xml · derivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,065 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 31, 2008 Filed Aug 4, 2008 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,353 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001104659-08-049636 · a4.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,353 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 31, 2008 Filed Aug 4, 2008 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,516 | $56.85 | $199,884.60 |
DisclosureSEC source: 0001104659-08-049636 · a4.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,512 Read SEC document |
| July 31, 2008 Filed Aug 4, 2008 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,065 | $32.61 | $99,953.02 |
DisclosureSEC source: 0001104659-08-049636 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2008 Filed Aug 4, 2008 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,353 | $42.50 | $99,997.32 |
DisclosureSEC source: 0001104659-08-049636 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2008 Filed Jul 11, 2008 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 8,156 | $0.00 Strike: $57.37 | $0.00 |
DisclosureSEC source: 0001104659-08-045356 · a4.xml · derivative · entry 5 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,156 Underlying: Common Shares · 8,156 shares Expires 2011-02-08 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 09, 2008 Filed Jul 11, 2008 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,330 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001104659-08-045356 · a4.xml · derivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Shares · 9,330 shares Expires 2011-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 09, 2008 Filed Jul 11, 2008 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,156 | $57.37 | $467,909.72 |
DisclosureSEC source: 0001104659-08-045356 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,610 Read SEC document |
| July 09, 2008 Filed Jul 11, 2008 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,330 | $45.45 | $424,037.30 |
DisclosureSEC source: 0001104659-08-045356 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2008 Filed Mar 5, 2008 01:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,033 | $54.22 | $56,009.26 |
DisclosureSEC source: 0001104659-08-015218 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,436 Read SEC document |
| February 29, 2008 Filed Mar 5, 2008 01:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 334 | $53.98 | $18,030.32 |
DisclosureSEC source: 0001104659-08-015218 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,469 Read SEC document |
| February 19, 2008 Filed Feb 20, 2008 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 591 | $55.98 | $33,084.18 |
DisclosureSEC source: 0001104659-08-011836 · a4.xml · nonDerivative · entry 4 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,803 Read SEC document |
| February 18, 2008 Filed Feb 20, 2008 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 511 | $55.55 | $28,386.05 |
DisclosureSEC source: 0001104659-08-011836 · a4.xml · nonDerivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,394 Read SEC document |
| February 17, 2008 Filed Feb 20, 2008 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,227 | $55.55 | $68,159.85 |
DisclosureSEC source: 0001104659-08-011836 · a4.xml · nonDerivative · entry 2 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,905 Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 55,200 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011836 · a4.xml · derivative · entry 6 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,200 Underlying: common shares · 55,200 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,400 on 02/15/2009, 18,400 on 02/15/2010, and 18,400 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,600 | $55.56 | $755,616.00 |
DisclosureSEC source: 0001104659-08-011836 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,132 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,775 | $0.00 Strike: $56.30 | $0.00 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · derivative · entry 15 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 1,775 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,775 | $56.40 | $100,110.00 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · nonDerivative · entry 11 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,532 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,775 | $56.30 | $99,932.50 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · nonDerivative · entry 10 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 242 | $0.00 Strike: $53.18 | $0.00 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · derivative · entry 14 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 242 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,805 | $0.00 Strike: $48.72 | $0.00 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · derivative · entry 13 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 6,805 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 159 | $56.75 | $9,023.57 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · nonDerivative · entry 9 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,532 Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,400 | $56.75 | $192,963.60 |
DisclosureSEC source: 0001104659-08-009506 · a4.xml · nonDerivative · entry 8 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,691 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.